Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 31.9 kDa. The protein migrates as 38-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Mouse N-APP, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Mouse N-APP, His Tag (Cat. No. APP-M52H3) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Donanemab | LY-3002813; LY-3002813-IV; LY-3002813-SC | Approved | Eli Lilly And Company | Kisunla, 记能达 | United States | Alzheimer Disease | Eli Lilly And Company | 2024-07-02 | Neurocognitive Disorders; Brain Diseases; Alzheimer Disease; Cognitive Dysfunction; Dementia; Tauopathies; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurodegenerative Diseases; Cognition Disorders | Details |
Sodium Oligomannurarate | GV-971; 971 | Approved | Ocean University Of China, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 九期一 | Mainland China | Alzheimer Disease | Shanghai Greenvalley Pharmaceutical Co Ltd | 2019-11-02 | Alzheimer Disease; Parkinson Disease; Cognition Disorders | Details |
Flutemetamol (18F) | AH-110690; GE-067; 18F-GE067 | Approved | Ge Healthcare | Vizamyl | United States | Contrast agents | Ge Healthcare | 2013-10-25 | Atherosclerosis; Cardiomyopathies; Contrast agents; Breast Neoplasms; Cognitive Dysfunction; Alzheimer Disease; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure; Cognition Disorders | Details |
Inositol | 4L6452S749 | Approved | Nicosit | Anovulation; Depression; Anxiety; Diabetic Neuropathies; Insulin Resistance; Polycystic Ovary Syndrome; Glucose Intolerance; Infant, Newborn, Diseases; Bronchopulmonary Dysplasia; Metabolic Diseases; Lung Neoplasms; Retinopathy of Prematurity; Precancerous Conditions; Premature Birth; Hyperandrogenism; Carcinoma, Non-Small-Cell Lung | Details | |||||
Immune globulin 10% (Grifols) | KIg-10; TAL-05-0002 | Approved | Bayer AG | Gamunex, Gammaked | United States | Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | null | 2003-08-27 | Postural Orthostatic Tachycardia Syndrome; Kidney Failure, Chronic; Immunologic Deficiency Syndromes; Corneal Neovascularization; Common Variable Immunodeficiency; Muscular Diseases; Neuralgia; Reflex Sympathetic Dystrophy; Obsessive-Compulsive Disorder; Severe Combined Immunodeficiency; Primary Immunodeficiency Diseases; Autoimmune Diseases; Anxiety Disorders; Coronavirus Disease 2019 (COVID-19); Agammaglobulinemia; Wiskott-Aldrich Syndrome; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Tibial Fractures; Myasthenia Gravis | Details |
Florapronol (18F) | 18F-FC-119S; 18F-FC-119(S) | Approved | Korea Institute Of Radiological And Medical Sciences, Futurechem | Alzavue | Alzheimer Disease | Details | ||||
Aducanumab | BIIB-037; NI-10; BART | Approved | Neurimmune Ag | ADUHELM | United States | Alzheimer Disease | Biogen Inc | 2021-06-07 | Alzheimer Disease; Dementia; Cognitive Dysfunction | Details |
L-Lysine hydrochloride/Cyanocobalamin/Inositol | Approved | 兴邦 | Malnutrition | Details | ||||||
Immune Globulin Subcutaneous (Human) (Octapharma) | Approved | Octapharma | Cutaquig, Octanorm, Gammanorm | United States | Immunologic Deficiency Syndromes | null | 2018-08-02 | Primary Immunodeficiency Diseases; Dermatomyositis; Immunologic Deficiency Syndromes | Details | |
Florbetaben (18F) | MNI-815; AV-1; ZK-6013443; BAY-949172; 18F-AV-1; 18F-AV1/ZK; AV-1/ZK; BAY 94-9172; UNII-TLA7312TOI | Approved | Piramal | Neuraceq, 欧韦宁 | EU | Alzheimer Disease | Life Radiopharma Berlin Gmbh | 2014-02-20 | Supranuclear Palsy, Progressive; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Contrast agents; Amyloidosis; Alzheimer Disease; Dementia; Dengue | Details |
Lecanemab | BAN-2401 | Approved | Bioarctic Neuroscience | Leqembi, LEQEMBI, 乐意保 | United States | Alzheimer Disease | Eisai Inc | 2023-01-06 | Alzheimer Disease; Dementia; Cognitive Dysfunction | Details |
Florbetapir(18F) | MNI-798; AV-45 | Approved | Eli Lilly And Company | Amyvid | United States | Spasms, Infantile; Rheumatic Diseases; Respiration Disorders; Multiple Sclerosis; Collagen Diseases; Skin Diseases; Hypersensitivity; Eye Diseases | Avid Radiopharmaceuticals Inc | 2012-04-06 | Respiration Disorders; Glioblastoma; Multiple Sclerosis; Skin Diseases; Spasms, Infantile; Alzheimer Disease; Cognitive Dysfunction; Rheumatic Diseases; Parkinson Disease; Diagnostic agents; Collagen Diseases; Eye Diseases; Lewy Body Disease; Neurodegenerative Diseases; Hypersensitivity; Frontotemporal Dementia | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Alzheimer Disease; Parkinson Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
Gantenerumab | MAb-31; R-1450; RG-1450; R-04909832 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Alzheimer Disease; Dementia | Details |
Valiltramiprosate | BLU-8499; NRM-8499; ALZ-801 | Phase 3 Clinical | Alzheon Inc | Alzheimer Disease | Details |
Solanezumab | LY-2062430 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia; Cognition Disorders | Details |
Tramiprosate | 3-APS; NC-531; NC-758 | Phase 3 Clinical | Bellus Health Inc | Stroke; Glaucoma; Alzheimer Disease | Details |
Birtamimab | NEOD-001 | Phase 3 Clinical | Prothena | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
Remternetug | LY-3372993 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia | Details |
RP-902 | RP902; RP-902 | Phase 3 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Alzheimer Disease | Details |
GAL-101 | EG-030; GAL-101; MRZ-99030 | Phase 2 Clinical | Tel Aviv University Trust | Glaucoma; Geographic Atrophy | Details |
L-clausenamide | Phase 2 Clinical | Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd | Dementia; Cognitive Dysfunction; Memory Disorders | Details | |
Crenezumab | MABT-5102-A; RG-7412; R-7412; RO-5490245 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
11C-BF-227 | 11C-BF-227; [11C]BF-227 | Phase 2 Clinical | Tohoku University | Diagnostic agents | Details |
Pittsburgh Compound B | [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB | Phase 2 Clinical | The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet | Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Dementia; Alcoholism; Alzheimer Disease; Parkinson Disease | Details |
CT-1812 | CT-1812; SV-119 | Phase 2 Clinical | Cogrx | Alzheimer Disease; Lewy Body Disease; Cognition Disorders; Macular Degeneration | Details |
[18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
Edonerpic | T-817 MA | Phase 2 Clinical | Toyama Chemical Co Ltd, Fujifilm Group | Cognitive Dysfunction; Alzheimer Disease; Hepatic Insufficiency | Details |
ABvac-40 | ABvac-40 | Phase 2 Clinical | Araclon Biotech Sl | Cognitive Dysfunction; Alzheimer Disease | Details |
PK-051 | PK051; PK-051 | Phase 2 Clinical | PharmaKure Ltd | Alzheimer Disease; Cognitive Dysfunction | Details |
PRI-002 | RD-2; PRI-002 | Phase 2 Clinical | PRInnovation GmbH, Priavoid | Alzheimer Disease; Cognitive Dysfunction | Details |
18F-92 | 18F-92 | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Alzheimer Disease | Details |
Mivelsiran | ALN-APP | Phase 2 Clinical | Sirna Therapeutics Inc | Cerebral Amyloid Angiopathy; Alzheimer Disease | Details |
SHR-1707 | SHR-1707 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Alzheimer Disease | Details |
ezeprogind | AZP-2006 | Phase 2 Clinical | Alzprotect | Supranuclear Palsy, Progressive; Alzheimer Disease | Details |
[18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | Details |
Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
APH-1105 | APH-1105 | Phase 2 Clinical | Aphios Corporation | Alzheimer Disease; Dementia | Details |
RIV-1061-IR | RIV-1061; RIV-1061-IR | Phase 1 Clinical | Revivo Therapeutics | Alzheimer Disease; Cognition Disorders | Details |
A ß antibody Fab | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
RQ-9 | AAT-009; RQ-9; RQ-00000009 | Phase 1 Clinical | Pfizer Inc | Dementia | Details |
MDR-1339 | DBT-1339; MDR-1339 | Phase 1 Clinical | Medifron | Alzheimer Disease | Details |
ADx-001 | Phase 1 Clinical | University Of Houston | Dementia; Alzheimer Disease | Details | |
TML-6 | TML-6 | Phase 1 Clinical | Merry Life Biomedical Co Ltd | Alzheimer Disease | Details |
AV-1959D | AV 1959D; AV-1959D | Phase 1 Clinical | Institute For Molecular Medicine, University Of California, Flinders University | Alzheimer Disease | Details |
ALZ-101 | ALZ-101 | Phase 1 Clinical | Alzinova AB | Alzheimer Disease; Dementia | Details |
PRX-012 | PRX-012 | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
PMN-310 | huPMN-310; PMN-310 | Phase 1 Clinical | ProMIS Neurosciences Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy | Details |
AS-S603 | AS-S603 | Phase 1 Clinical | Amyloid Solution Inc | Details | |
ION-269 | ION-269; ION269 | Phase 1 Clinical | Ionis Pharmaceuticals Inc | Down Syndrome; Alzheimer Disease | Details |
ALIA-1758 | ALIA-1758 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Alzheimer Disease | Details |
CM-383 | CM383; CM-383 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Alzheimer Disease; Cognitive Dysfunction | Details |
OAB-14 | OAB-14 | Phase 1 Clinical | Shenyang Pharmaceutical University | Alzheimer Disease | Details |
BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
Abeta42 antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Smoking Cessation; Thyroiditis, Autoimmune; Tobacco Use Disorder; Alzheimer Disease; Inflammation | Details |
123I-ABC-577 | 123I-ABC-577 | Clinical | Nihon Medi-Physics Co Ltd | Diagnostic agents | Details |
Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic | Details | |
Procaine Hydrochloride/Vitamin B6/Inositol | Details | ||||
Inositol/Vitamin B1/Vitamin B2 | Details |
This web search service is supported by Google Inc.